Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micronised progesterone for transfeminine individuals on estradiol
ACTRN12620001130954Phase 4Not yet recruiting
- Sponsor
- Austin Health
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of progesterone in Gender incongruence (GI) (2 arms), sponsored by Austin Health. Primary endpoint: Sleep quality. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
progesterone
03
Conditions
Gender incongruence (GI)
Beyond the preview
Go deeper on ACTRN12620001130954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001130954.